What Is Mounjaro Used For? Approved Uses, Off-Label Uses, and What's Inside the Pen

Key Takeaways

• Mounjaro is FDA-approved to improve blood sugar control in adults with type 2 diabetes. That's the only on-label use.
• The active ingredient is tirzepatide, a once-weekly injection that activates both GLP-1 and GIP receptors.
• It's commonly prescribed off-label for weight loss in adults without diabetes, though tirzepatide is FDA-approved for weight management under the separate brand Zepbound.
• It's made by Eli Lilly and Company, headquartered in Indianapolis.
• It's not insulin and not a stimulant. It works by mimicking gut hormones that regulate appetite and blood sugar.

Direct answer (40-60 words)

Mounjaro is FDA-approved for type 2 diabetes in adults, used as an adjunct to diet and exercise to improve blood sugar control. It's also widely prescribed off-label for weight loss. The active ingredient is tirzepatide, a once-weekly injection that activates both GLP-1 and GIP receptors. The same drug is approved for weight management under the brand name Zepbound.

Table of contents

1. The 30-second answer
2. What Mounjaro is FDA-approved to treat
3. Off-label use for weight loss
4. How Mounjaro works in your body
5. Mounjaro dosing in one paragraph
6. Side effects and warnings
7. Mounjaro vs Zepbound: same drug, different brand
8. Mounjaro vs Ozempic and Wegovy
9. Cost, insurance, and access
10. Compounded tirzepatide: same active ingredient, different product
11. FAQ
12. Sources
13. Footer disclaimers

What Mounjaro is FDA-approved to treat

Mounjaro has one FDA-approved indication: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The drug was approved on May 13, 2022, based on the SURPASS clinical trial program, which showed that tirzepatide produced larger reductions in HbA1c than both placebo and active comparators (semaglutide, insulin degludec, and insulin glargine) across multiple SURPASS trials (SURPASS-1 through SURPASS-5, NEJM and Lancet 2021 to 2022).

What Mounjaro is not approved for:

• Weight loss without diabetes (a separate brand, Zepbound, is approved for that)
• Type 1 diabetes
• Diabetic ketoacidosis
• Use in children under 18

The same molecule, tirzepatide, is FDA-approved for chronic weight management under the brand name Zepbound (approved November 2023). Same drug, different brand, different approved use, similar dose ranges.

Off-label use for weight loss

Many providers prescribe Mounjaro off-label for weight loss in patients without type 2 diabetes. "Off-label" means the FDA hasn't reviewed and approved that specific use, but a licensed provider can legally prescribe an approved drug for a different condition based on clinical judgment.

The off-label use exists because:

• Tirzepatide produces meaningful weight loss as a side effect of the diabetes treatment, with average loss of 15 to 21% of baseline body weight at 72 weeks (Jastreboff et al., New England Journal of Medicine 2022, SURMOUNT-1).
• Insurance coverage for diabetes (Mounjaro) is broader than for weight loss (Zepbound), so some patients access tirzepatide through Mounjaro coverage even when weight is the primary clinical concern.
• The drug is the same molecule. The off-label and on-label use produce the same biological effect.

Insurance billing for off-label Mounjaro use is increasingly restricted as Zepbound coverage expands. Many payers now require a documented diabetes diagnosis for Mounjaro and direct weight-loss patients to Zepbound.

For more on the difference, see our Mounjaro vs Zepbound comparison.

How Mounjaro works in your body

Tirzepatide is a "dual agonist." It activates two different gut hormone receptors at once:

GLP-1 receptors. Found in the pancreas, stomach, brain, and intestines. Activation causes:

• Glucose-dependent insulin release (insulin only goes up when blood sugar is high, so hypoglycemia is rare)
• Suppression of glucagon (the hormone that raises blood sugar)
• Slowed gastric emptying (food stays in the stomach longer, prolonging fullness)
• Reduced appetite signaling in the hypothalamus

GIP receptors. Found in the pancreas, fat tissue, and brain. Activation causes:

• Additional glucose-dependent insulin release
• Effects on fat metabolism that may reduce ectopic fat (fat in the liver and around organs)
• Possible reduction in nausea side effects compared to GLP-1 alone

The combined GLP-1 and GIP activation produces stronger blood sugar control and weight loss than GLP-1 activation alone in head-to-head trials (Frias et al., New England Journal of Medicine 2021, SURPASS-2).

The half-life is about 5 days. That's why Mounjaro is a once-weekly injection.

Mounjaro dosing in one paragraph

Mounjaro starts at 2.5 mg once weekly for 4 weeks. After 4 weeks, dose increases to 5 mg once weekly. Further increases are made in 2.5 mg increments at intervals of at least 4 weeks if needed for additional blood sugar control. Available doses are 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. The 2.5 mg starting dose is for tolerability, not therapeutic effect; meaningful HbA1c lowering and weight loss start at 5 mg and above.

For more, see our Mounjaro dosing schedule and tirzepatide dosage chart.

Side effects and warnings

The most common side effects in clinical trials of Mounjaro for type 2 diabetes (Frias et al., NEJM 2021; Ludvik et al., Lancet 2021):

• Nausea (12 to 18%)
• Diarrhea (12 to 17%)
• Decreased appetite (5 to 11%)
• Vomiting (5 to 9%)
• Constipation (6 to 7%)
• Indigestion (5 to 8%)
• Abdominal pain (5 to 6%)

Most of these peak in the first 4 to 8 weeks and fade. Slow titration (sticking with each dose level for at least 4 weeks before going up) reduces peak intensity.

Boxed warning: thyroid C-cell tumors. Rodent studies showed an increased risk of medullary thyroid cancer with GLP-1 receptor agonists, including tirzepatide. Whether this risk extends to humans is unclear. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Other warnings:

• Pancreatitis. Stop the drug and evaluate if severe persistent abdominal pain occurs.
• Gallbladder disease. Higher rates of gallstones and acute gallbladder inflammation in trials.
• Acute kidney injury, usually in patients with severe vomiting and dehydration.
• Severe hypersensitivity reactions (rare).
• Diabetic retinopathy complications in patients with pre-existing retinopathy on rapid HbA1c reduction.
• Hypoglycemia, primarily when used with sulfonylureas or insulin.

For more, see our tirzepatide side effects guide.

Mounjaro vs Zepbound: same drug, different brand

This is the most common source of confusion. Mounjaro and Zepbound are the same molecule (tirzepatide), made by the same company (Eli Lilly), and use similar dose strengths.

The drug inside the pen is identical. The brand difference is regulatory and packaging. A doctor prescribing tirzepatide for a patient with type 2 diabetes uses Mounjaro. A doctor prescribing tirzepatide for weight management without diabetes uses Zepbound. The clinical effect is the same.

Mounjaro vs Ozempic and Wegovy

Mounjaro is sometimes compared to Ozempic and Wegovy because all three are once-weekly injectable medications used for diabetes and/or weight management.

In the SURPASS-2 head-to-head trial, tirzepatide outperformed semaglutide on HbA1c reduction and weight loss in patients with type 2 diabetes (Frias et al., NEJM 2021). The trial used 1 mg semaglutide weekly, which is a sub-maximum dose; results at higher semaglutide doses may be closer.

For a more detailed comparison, see our tirzepatide vs semaglutide guide.

Cost, insurance, and access

Mounjaro list price in 2026 is approximately $1,069 per 28-day supply (4 weekly pens). The Eli Lilly Savings Card can reduce out-of-pocket cost to $25 per month for commercially insured patients with coverage, or to $573 per month if Mounjaro is not covered.

Insurance coverage for type 2 diabetes is generally broader than for weight management. A patient with documented type 2 diabetes typically has a clearer path to insurance approval for Mounjaro than a patient seeking off-label use for weight loss.

Eli Lilly has expanded production capacity through new manufacturing facilities, including a $9 billion investment announced in 2024 for additional U.S. fill-finish capacity. Mounjaro and Zepbound supply has stabilized after intermittent shortages between 2022 and 2024.

For more, see our Mounjaro savings card guide and why tirzepatide is expensive.

Compounded tirzepatide: same active ingredient, different product

During the 2022 to 2024 tirzepatide shortage, FDA-licensed compounding pharmacies were permitted to prepare compounded tirzepatide under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded tirzepatide uses the same active ingredient but is not FDA-approved, has not been through the FDA's review process, and is not interchangeable with Mounjaro or Zepbound.

The FDA declared the tirzepatide shortage resolved in late 2024, which has narrowed the conditions under which 503A compounding can continue. 503B outsourcing facilities operate under stricter manufacturing standards and remain a separate category.

If you've been receiving compounded tirzepatide, ask your provider about transitioning to FDA-approved Mounjaro or Zepbound as supply has improved. The clinical effect is similar; the regulatory status is different.

FAQ

What is Mounjaro used for? Mounjaro is FDA-approved for type 2 diabetes in adults, used as an adjunct to diet and exercise to improve blood sugar control. It's also widely prescribed off-label for weight loss, though the same drug, tirzepatide, is FDA-approved for weight management under the brand Zepbound.

Is Mounjaro a weight-loss drug? Mounjaro is not FDA-approved for weight loss. It causes substantial weight loss as part of its mechanism, and it's prescribed off-label for that purpose, but the FDA-approved weight-loss version is Zepbound, not Mounjaro.

What is the active ingredient in Mounjaro? Tirzepatide. It's a once-weekly injectable peptide that activates both GLP-1 and GIP receptors.

Who makes Mounjaro? Eli Lilly and Company, an American pharmaceutical company headquartered in Indianapolis, Indiana. Eli Lilly also makes Zepbound (the same drug for weight management) and a line of diabetes medications including insulin.

How is Mounjaro different from Ozempic? Mounjaro is tirzepatide (a dual GLP-1 and GIP agonist). Ozempic is semaglutide (a GLP-1 agonist only). Tirzepatide produces somewhat larger HbA1c reductions and weight loss in head-to-head trials. Different manufacturers (Lilly vs Novo Nordisk).

How is Mounjaro different from Zepbound? Same drug, same manufacturer, different brand and FDA-approved use. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Dose strengths overlap. Pen format differs (Mounjaro is a multi-dose KwikPen; Zepbound is a single-dose pen).

Is Mounjaro insulin? No. Mounjaro is a GLP-1/GIP receptor agonist. It causes the pancreas to release more insulin in a glucose-dependent way (only when blood sugar is high), but the drug itself is not insulin.

How long does it take Mounjaro to work? Blood sugar typically starts dropping within the first 1 to 2 weeks. Weight loss begins within the first month and continues over roughly 18 months before plateauing. Maximum HbA1c reduction is usually seen by 12 to 16 weeks at a stable dose.

Can I use Mounjaro long-term? Yes. Trial data extends to 1 to 2 years and observational data is expanding past 3 years. Tirzepatide is treated as a chronic-use medication for both diabetes and weight management. Stopping the drug typically results in regaining most of the lost weight (Aronne et al., JAMA 2024, SURMOUNT-4).

Does Mounjaro cause hypoglycemia? On its own, rarely. Mounjaro's insulin release is glucose-dependent, so it doesn't drive blood sugar below normal in patients without other glucose-lowering drugs. Risk goes up when combined with sulfonylureas or insulin.

Is Mounjaro safe during pregnancy? No. Mounjaro is contraindicated in pregnancy. Stop the drug and contact your provider if you become pregnant or are trying to become pregnant. Tirzepatide may also reduce the effectiveness of oral contraceptives for the first 4 weeks of treatment and after each dose increase.

Does Mounjaro lower cholesterol? Tirzepatide trials have shown modest reductions in triglycerides and LDL cholesterol, alongside the larger effects on blood sugar and weight. The cardiovascular benefit at scale is being studied in ongoing trials.

Sources

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
2. Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin (SURPASS-3). Lancet. 2021;398:583-598.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
4. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331:38-48.
5. FDA. Mounjaro (tirzepatide injection) prescribing information. Approved May 2022; current label revision 2024.
6. FDA. Zepbound (tirzepatide injection) prescribing information. Approved November 2023; current label revision 2024.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and KwikPen are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by either company.